

## ZP 120C

|                             |   |
|-----------------------------|---|
| <b>Cat. No.:</b>            | HY-106234   |
| <b>CAS No.:</b>             | 383123-18-0   |
| <b>Molecular Formula:</b>   | C <sub>85</sub> H <sub>27</sub> N <sub>15</sub> O <sub>15</sub>                           |
| <b>Molecular Weight:</b>    | 1781.2  |
| <b>Sequence Shortening:</b> | Ac-RYYRWKKKKKKK-NH2   |
| <b>Target:</b>              | Opioid Receptor   |
| <b>Pathway:</b>             | GPCR/G Protein; Neuronal Signaling  |
| <b>Storage:</b>             | Please store the product under the recommended conditions in the Certificate of Analysis. |

### BIOLOGICAL ACTIVITY

|                                     |   |  |                      |   |                |             |                        |  |                |  |
|-------------------------------------|---|--|----------------------|---|----------------|-------------|------------------------|--|----------------|--|
| <b>Description</b>                  | ZP 120C is a potent and partial ORL1 receptor agonist. ZP 120C inhibits electrically induced contraction. ZP 120C can be used in the research of hyponatremia/hypokalemia <sup>[1][3]</sup> .   |  |                      |   |                |             |                        |  |                |  |
| <b>IC<sub>50</sub> &amp; Target</b> | NOP Receptor/ORL1   |  |                      |   |                |             |                        |  |                |  |
| <b>In Vitro</b>                     | <p>ZP 120C (1 nM) inhibits electrically induced contraction of the mouse vas deferens<sup>[2]</sup>.</p> <p>ZP 120C (1 μM) inhibits electrical field stimulation (EFS)-induced contractions in rat arteries<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>   |  |                      |   |                |             |                        |  |                |  |
| <b>In Vivo</b>                      | <p>ZP 120C (1 nM/kg/min, i.v., 2.5 h) displays an aquaretic effect in conscious, chronically instrumented rats with congestive heart failure (CHF)<sup>[1]</sup></p> <p>.ZP 120C (1 nM, i.c.v., 30 min) produces pronociceptive effects in the tail withdrawal assay and decreases locomotor activity in mice<sup>[2]</sup></p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td><b>Animal Model:</b></td> <td>Rats induced by left coronary artery ligation (LCAL)<sup>[1]</sup></td> </tr> <tr> <td><b>Dosage:</b></td> <td>1 nM/kg/min</td> </tr> <tr> <td><b>Administration:</b></td> <td>Intravenous injection (i.v.), 2.5 h of constant intravenous infusion</td> </tr> <tr> <td><b>Result:</b></td> <td>Increased diuresis, free water clearance, fractional water excretion, and fractional distal water excretion.</td> </tr> </table> |  | <b>Animal Model:</b> | Rats induced by left coronary artery ligation (LCAL) <sup>[1]</sup> | <b>Dosage:</b> | 1 nM/kg/min | <b>Administration:</b> | Intravenous injection (i.v.), 2.5 h of constant intravenous infusion | <b>Result:</b> | Increased diuresis, free water clearance, fractional water excretion, and fractional distal water excretion. |
| <b>Animal Model:</b>                | Rats induced by left coronary artery ligation (LCAL) <sup>[1]</sup>   |  |                      |   |                |             |                        |  |                |  |
| <b>Dosage:</b>                      | 1 nM/kg/min   |  |                      |   |                |             |                        |  |                |  |
| <b>Administration:</b>              | Intravenous injection (i.v.), 2.5 h of constant intravenous infusion  |  |                      |   |                |             |                        |  |                |  |
| <b>Result:</b>                      | Increased diuresis, free water clearance, fractional water excretion, and fractional distal water excretion.  |  |                      |   |                |             |                        |  |                |  |

### REFERENCES

[1]. Hadrup N, et al. Opioid receptor-like 1 stimulation in the collecting duct induces aquaresis through vasopressin-independent aquaporin-2 downregulation. *Am J Physiol Renal Physiol*. 2004 Jul;287(1):F160-8.

[2]. Rizzi A, et al. Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice. *Br J Pharmacol*. 2002

---

Oct;137(3):369-74.

[3]. Simonsen U, et al. ZP120 causes relaxation by pre-junctional inhibition of noradrenergic neurotransmission in rat mesenteric resistance arteries. Br J Pharmacol. 2008 Mar;153(6):1185-94.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA